Abivax (ABVX) Research & Development (2022 - 2026)
Abivax (ABVX) reported Research & Development of $67.81 million for Q2 2026, up 55.0% from $43.74 million a year earlier and up 16.9% from the prior quarter.
Powered by 
Analysis
Abivax (ABVX) Research & Development (2022 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Abivax's Research & Development came in at $242.27 million, up 82.7% year-over-year; for FY2025, it was $200.84 million, up 26.6% from FY2024.
- Research & Development has increased for three consecutive years, with a four-year compound annual growth rate of 37.3% (FY2021 to FY2025).
- By year, Research & Development came in at $158.6 million in FY2024 (+42.1%), $111.61 million in FY2023 (+119.3%), $50.9 million in FY2022 (-10.0%) and $56.54 million in FY2021.
- The Q2 2026 figure ranks as the highest quarterly Research & Development in data going back to Q4 2022.
- Per Business Quant data, the three quarters before Q2 2026 came in at $58 million (Q1 2026), $51.68 million (Q4 2025) and $64.78 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 3.89 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Abivax | 7.07 Bn | 4.69 Bn | - | 67.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 67.81 Mn |
| Mar 31, 2026 | 58.00 Mn |
| Dec 31, 2025 | 51.68 Mn |
| Sep 30, 2025 | 64.78 Mn |
| Jun 30, 2025 | 43.74 Mn |
| Mar 31, 2025 | 41.34 Mn |
| Dec 31, 2024 | 156.55 |
| Sep 30, 2024 | 47.54 Mn |
| Jun 30, 2024 | 31.13 Mn |
| Mar 31, 2024 | 38.83 Mn |
| Dec 31, 2023 | 111.04 |
| Dec 31, 2022 | 49.28 |
API Access
Abivax Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ABVX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ABVX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ABVX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();